Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical …

…, P Hannonen, J Asikainen, A Kokko… - Expert opinion on …, 2015 - Taylor & Francis
Full article: Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from
Remicade (infliximab) in patients with established rheumatic disease. Report of clinical …

[PDF][PDF] Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics

…, J Asikainen, IJ Widding Hansen, A Kokko… - Clin Exp …, 2013 - clinexprheumatol.org
Objective Selection of efficacious medications for rheumatoid arthritis (RA) has tremendously
increased over a decade including new costly biologic agents and inexpensive …

Early remission is a realistic target in a majority of patients with DMARD-naive rheumatoid arthritis

T Rannio, J Asikainen, A Kokko, P Hannonen… - The Journal of …, 2016 - jrheum.org
Objective. We analyzed remission rates at 3 and 12 months in patients with rheumatoid arthritis
(RA) who were naive for disease-modifying antirheumatic drugs (DMARD) and who were …

[PDF][PDF] Survival and safety of infliximab bio-original and infliximab biosimilar (CT-P13) in usual rheumatology care

…, J Asikainen, J Borodina, A Kokko… - Clin Exp …, 2019 - clinexprheumatol.org
Objective Reports to-date indicate similarity between infliximab biosimilar (IB) and infliximab
bio-original (IO) in clinical efficacy and safety. This study examines the survival of IB and IO …

Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseases

…, P Isomäki, H Mäkinen, KL Vidqvist, A Kokko… - …, 2022 - Taylor & Francis
Introduction The prevalence of immune-mediated diseases has increased in the past decades
and despite the use of biological treatments all patients do not achieve remission. The …

[HTML][HTML] Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis

…, FinADASpA Study Group Kokko Arto Kononoff … - Rheumatology …, 2022 - Springer
Key messages Considerable proportion of patients with SpA have been immunized to the
subcutaneous anti-TNF drug they are using. Concomitant use of MTX protects from …

Results from Finland's 2014 report card on physical activity for children and youth

J Liukkonen, T Jaakkola, S Kokko… - … of Physical Activity …, 2014 - journals.humankinetics.com
The Finnish 2014 Report Card on Physical Activity (PA) for Children and Youth is the first
assessment of Finland’s efforts in promoting and facilitating PA opportunities for children and …

[HTML][HTML] Long-term population effects of infant 10-valent pneumococcal conjugate vaccination on pneumococcal meningitis in Finland

A Polkowska, H Rinta-Kokko, M Toropainen, AA Palmu… - Vaccine, 2021 - Elsevier
Background No previous studies have reported long-term follow-up of ten-valent pneumococcal
conjugate vaccine (PCV10) program impact on pneumococcal meningitis (PM). We …

[CITATION][C] Automated Cell Phone Monitoring of Disease Activity and Medication Adherence in Early Rheumatoid Arthritis

…, K Paalanen, A Kokko… - ARTHRITIS & …, 2016 - … ST, HOBOKEN 07030-5774, NJ USA

[CITATION][C] EARLY RHEUMATOID ARTHRITIS IN JYVASKYLA 2008-11; DESCRIPTION OF PATIENTS SEEN IN NORMAL CLINICAL CARE

T Rannio, J Asikainen, A Kokko… - …, 2012 - … TELEPHONE HOUSE, 69-77 PAUL …